B of A Securities Maintains Buy on Sage Therapeutics, Raises Price Target to $61
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Tazeen Ahmad maintains a Buy rating on Sage Therapeutics (NASDAQ:SAGE) and raises the price target from $56 to $61.
May 23, 2023 | 11:57 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B of A Securities maintains a Buy rating on Sage Therapeutics and raises the price target from $56 to $61.
The Buy rating maintained by B of A Securities and the increased price target from $56 to $61 indicate a positive outlook for Sage Therapeutics. This news is likely to have a positive impact on the stock price in the short term as it reflects the analyst's confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100